No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases

Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent

Improving cancer care outcomes in Ghana through mentorship

Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC